Get the Stockscreener App
92.41
1.16%
1.06
After Hours:
93.00
0.59
+0.64%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $92.41, with a volume of 4.22M.
It is up +1.16% in the last 24 hours and up +3.83% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$91.35
Open:
$91.44
24h Volume:
4.22M
Relative Volume:
0.68
Market Cap:
$115.18B
Revenue:
$28.30B
Net Income/Loss:
$126.00M
P/E Ratio:
21.24
EPS:
4.35
Net Cash Flow:
$9.43B
1W Performance:
+4.26%
1M Performance:
+3.83%
6M Performance:
+40.70%
1Y Performance:
+23.34%
1-Day Range:
$91.44
$92.89
1-Week Range:
$88.07
$92.89
52-Week Range:
$62.07
$98.90
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
92.41 | 115.18B | 28.30B | 126.00M | 9.43B | 4.35 |
|
LLY
Lilly Eli Co
|
788.19 | 752.65B | 40.86B | 8.37B | -2.28B | 5.4193 |
|
NVO
Novo Nordisk Adr
|
106.13 | 471.56B | 39.36B | 13.79B | 9.83B | 2.4077 |
|
JNJ
Johnson Johnson
|
155.40 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
|
ABBV
Abbvie Inc
|
183.08 | 323.72B | 55.53B | 5.12B | 15.62B | 3.65 |
|
MRK
Merck Co Inc
|
103.12 | 260.72B | 63.17B | 12.15B | 14.84B | 1.80 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences director Jeffrey Bluestone sells $620,355 in stock - Investing.com India
Gilead reports high efficacy in HIV prevention trial - Investing.com
Gilead's HIV Prevention Drug Shows 96% Efficacy in Landmark Phase 3 Trial | GILD Stock News - StockTitan
Gilead's Scientific Innovation at the Forefront of Helping End the HIV Epidemic - Gilead Sciences
Lead Gilead researcher highlights need for inclusive clinical trials for HIV - Clinical Trials Arena
Kiltearn Partners LLP Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Gilead Gets $31.8M In Calif. Case Over Counterfeit HIV Drugs - Law360
A Legacy in Liver Disease TreatmentsSponsor ContentGilead - The Atlantic
Gilead awarded $30m over counterfeit HIV drug scheme - Life Sciences Intellectual Property Review
Antibody Drug Conjugate Market Industry Trends and Forecasts to 2035, Featuring Profiles of Key Players ADC Therapeutics, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, RemeGen and More - Yahoo Finance
Principal Street Partners LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic - AccessWire
Gilead Sciences' Breakthrough HIV Prevention Trial Shows Promise in African Women | GILD Stock News - StockTitan
Fmr LLC Raises Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Dai ichi Life Insurance Company Ltd Sells 205,601 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
The Manufacturers Life Insurance Company Sells 260,875 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech - Pharmaceutical Technology
Gilead Sciences acquires HTI vaccine from AELIX - The Pharma Letter
Toward Health Equity Oncology Grant™ – Cancer Funding - Gilead Sciences
Gilead Sciences' SWOT analysis: HIV giant faces growth hurdles as stock wavers - Investing.com
Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Gilead snaps up HIV jab from Barcelona-based research partner - FirstWord Pharma
Gilead buys HIV vaccine from Spanish biotech following success in clinical collab - Fierce Biotech
Price Over Earnings Overview: Gilead Sciences - Benzinga
Harvest Fund Management Co. Ltd Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Cerity Partners LLC Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Reduces Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Zacks Research Weighs in on Gilead Sciences FY2024 Earnings - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Daiwa Securities Group Inc. - MarketBeat
LPL Financial LLC Has $95.36 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Icon Wealth Advisors LLC - MarketBeat
Meridian Wealth Management LLC Invests $3.56 Million in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Eagle Asset Management Inc. Has $17.41 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Marginal Zone Lymphoma Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC - Barchart
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc. - Business Wire
Gilead Announces Layoffs Amid Strong Q3 Performance, HIV Drug Sa - GuruFocus.com
Q3 EPS Estimates for Gilead Sciences Increased by Analyst - MarketBeat
8,154 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Altiora Financial Group LLC - MarketBeat
Charles Schwab Investment Management Inc. Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Pacer Advisors Inc. Has $65.53 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Mizuho Securities USA LLC Trims Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Thompson Siegel & Walmsley LLC Buys 43,921 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Commerce Bank Purchases 7,055 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Layoff Tracker: Sonata Therapeutics Laying Off 20 Employees, Changing Leadership - BioSpace
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Sjogren’s Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Gilead Sciences, Incyte Corporation, Novartis, GlaxoSmithKline, Janssen Research & Development - Barchart
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $100.00 - MarketBeat
Gilead’s GS-6791 ameliorates arthritis symptoms in mice - BioWorld Online
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Commercial Officer |
Nov 06 '24 |
Sale |
91.28 |
5,000 |
456,400 |
73,127 |
| Parsey Merdad | Chief Medical Officer |
Nov 06 '24 |
Option Exercise |
57.92 |
25,000 |
1,448,000 |
125,189 |
| Parsey Merdad | Chief Medical Officer |
Nov 06 '24 |
Sale |
91.50 |
25,590 |
2,341,485 |
99,599 |
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):